Core Insights - CERo Therapeutics Holdings, Inc. is advancing its Phase 1 clinical trial of CER-1236 for acute myeloid leukemia (AML) at the Colorado Blood Cancer Institute, with patient enrollment currently underway and initial dosing expected by June 2025 [1][2][3] Company Overview - CERo is an innovative immunotherapy company focused on engineered T cell therapeutics that utilize phagocytic mechanisms to enhance cancer treatment [1][3] - The company’s proprietary T cell engineering approach aims to integrate characteristics of both innate and adaptive immunity, potentially offering greater therapeutic applications than current CAR-T therapies [3] Clinical Trial Details - The Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory AML, measurable residual disease, or TP53 gene mutations [2] - The trial will consist of a dose escalation phase to determine the highest tolerated dose, followed by an expansion phase to assess safety and efficacy [2] - Primary outcome measures include the incidence of adverse events, dose-limited toxicities, overall response rate, complete response, composite complete response, and measurable residual disease [2] Expert Commentary - Dr. Yazan Migdady from the Colorado Blood Cancer Institute highlighted the potential of chimeric engulfment receptor technology in improving treatment outcomes for AML patients [2]
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia